Review decision: March 2016
We checked this guideline and decided that it should be updated. For details, see the update decision, decision matrix and the process for deciding if an update is needed. Details of the update will be available on the guidelines in development webpage in due course. No further checks of this guideline will be scheduled until this update is published.
Next review date: TBC
In November 2015, we deleted recommendation 1.1.14 and replaced it with a link to updated advice in suspected cancer: recognition and referral (NICE guideline NG12), published in June 2015.
This guidance updates and replaces:
- Urinary incontinence (2006) NICE guideline CG40
- The clinical effectiveness and cost effectiveness of tension-free vaginal tape for stress incontinence (2003) NICE technology appraisal guidance 56
- Idiopathic overactive bladder syndrome: botulinum toxin A (2012) NICE advice ESNM2
It offers evidence-based advice on the care and treatment of women with urinary incontinence.
This guideline was previously called Urinary incontinence: The management of urinary incontinence in women.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.